Tempus AI, Inc. (TEM) Free Cash Flow (FCF): $-216.50M
The free cash flow (FCF) for Tempus AI, Inc. (TEM) is $-216.50M. It is above its 12-month average by 3.84% ($-225.15M).
TEM Free Cash Flow (FCF) Chart
TEM Average Free Cash Flow (FCF) Chart
TEM Current vs Average Free Cash Flow (FCF) Chart
TEM Free Cash Flow (FCF) Metrics
FREE CASH FLOW (FCF)
$-216.50M
FREE CASH FLOW (FCF) AVG TTM
$-225.15M
FREE CASH FLOW (FCF) AVG 3Y
$-221.46M
FREE CASH FLOW (FCF) AVG 5Y
$-221.59M
FREE CASH FLOW (FCF) AVG 10Y
$-209.10M
FREE CASH FLOW (FCF) AVG 15Y
$-209.10M
FREE CASH FLOW (FCF) AVG 20Y
$-209.10M
CURRENT VS TTM AVG
+3.84%
CURRENT VS 3Y AVG
+2.24%
CURRENT VS 5Y AVG
+2.30%
CURRENT VS 10Y AVG
-3.54%
CURRENT VS 15Y AVG
-3.54%
CURRENT VS 20Y AVG
-3.54%
FCF Analysis
Free Cash Flow (TTM)
$-216.50M
FCF Yield
N/A
Price/FCF
N/A
Formula: FCF = Operating Cash Flow - Capital Expenditures
Why FCF matters:
- Shows actual cash available (not accounting earnings)
- Funds dividends, buybacks, and debt reduction
- Less susceptible to accounting manipulation than net income
- Key metric for DCF valuation models
Tempus AI, Inc. Free Cash Flow (FCF) Formula & Definition
Free Cash Flow represents the cash a company generates after accounting for capital expenditures. It's the cash available for dividends, buybacks, debt reduction, or reinvestment.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Tempus AI, Inc. Free Cash Flow (FCF) FAQ
- What is the free cash flow (FCF) for Tempus AI, Inc. (TEM)?
- The free cash flow (FCF) for TEM stock is $-216.50M.
- What is the TTM average free cash flow (FCF) for Tempus AI, Inc. (TEM)?
- The TTM average free cash flow (FCF) for TEM stock is $-225.15M.
- What is the 3Y average free cash flow (FCF) for Tempus AI, Inc. (TEM)?
- The 3Y average free cash flow (FCF) for TEM stock is $-221.46M.
- What is the 5Y average free cash flow (FCF) for Tempus AI, Inc. (TEM)?
- The 5Y average free cash flow (FCF) for TEM stock is $-221.59M.
- What is the 10Y average free cash flow (FCF) for Tempus AI, Inc. (TEM)?
- The 10Y average free cash flow (FCF) for TEM stock is $-209.10M.
- What is the 15Y average free cash flow (FCF) for Tempus AI, Inc. (TEM)?
- The 15Y average free cash flow (FCF) for TEM stock is $-209.10M.
- What is the 20Y average free cash flow (FCF) for Tempus AI, Inc. (TEM)?
- The 20Y average free cash flow (FCF) for TEM stock is $-209.10M.
Tempus AI, Inc. Free Cash Flow (FCF) History
| DATE | FREE CASH FLOW (FCF) |
|---|---|
| 2025-12-31 | $-239.14M |
| 2024-12-31 | $-211.17M |
| 2023-12-31 | $-248.95M |
| 2022-12-31 | $-186.58M |
| 2021-12-31 | $-223.75M |
| 2020-12-31 | $-219.98M |
| 2019-12-31 | $-134.15M |
Related Metrics
About Tempus AI, Inc.
Tempus AI, Inc. functions as a pioneering health technology enterprise. It specializes in delivering advanced diagnostic services, including cutting-edge genomic sequencing, PCR analysis, molecular genotyping, and various other anatomical and molecular pathology assessments. These vital services are provided to a diverse clientele, including medical practitioners, pharmaceutical companies, biotechnology innovators, scientific researchers, and other collaborating entities. The company offers "Insights," a licensed repository of de-identified clinical, molecular, and imaging data, complemented by a comprehensive suite of analytical and cloud-based computing services, primarily aimed at pharmaceutical and biotechnology firms. Additionally, its "Trials" program facilitates clinical trial matching services specifically for pharmaceutical companies. Tempus AI also manages several other platforms: "Next"; "Algos," a collection of algorithm-driven tests focused on oncology; "Hub," a versatile desktop and mobile application for ordering, managing, and receiving test results for patients; and "Lens," a dedicated portal enabling researchers and scientists to discover, access, and analyze the extensive Tempus dataset. Further demonstrating its commitment to innovation, Tempus AI has formed strategic alliances with AstraZeneca and Pathos AI, Inc. for the co-development of oncological therapeutic initiatives. Established in 2015, the company was initially known as Tempus Labs, Inc. before officially rebranding to Tempus AI, Inc. in January 2023. Its operations are based out of Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Eric Lefkofsky